FrancophonIA/ELRC3.0 huggingface dataset:
English: 339 patients (225 verteporfin, 114 placebo) were enrolled in this study.
Slovenian: V študijo je bilo vključenih 339 bolnikov (225 verteporfin, 114 placebo).
English: The most frequently reported adverse reactions to Visudyne (verteporfin for infusion) are injection site reactions (including pain, oedema, inflammation, extravasation, rashes, haemorrhage, discolouration) and visual impairment (including blurred, fuzzy vision, photopsia, reduced visual acuity and visual field defects, including scotoma and black spots).
Slovenian: Neželeni učinki, o katerih so pri uporabi zdravila Visudyne (verteporfina za infundiranje) najbolj pogosto poročali, so reakcije na mestu injiciranja (ki vključujejo bolečino, edem, vnetje, ekstravazacijo, izpuščaje, krvavitev, spremenjeno barvo) in motnje vida (ki vključujejo zamegljen, zabrisan vid, fotopsijo, zmanjšanje ostrine vida in izpade vidnega polja, vključno s skotomi in črnimi pegami).
English: • General disorders: Hypersensitivity (allergic reactions), syncope (fainting), headache, lightheadedness, breathlessness.
Slovenian: • Splošne težave: preobčutljivost (alergijske reakcije), sinkopa (nenadna izguba zavesti), glavobol, omotica, zadihanost.
English: Visudyne contains small amounts of butylated hydroxytoluene (E321) This ingredient is irritant to eyes, skin and mucous membranes.
Slovenian: Zdravilo Visudyne vsebuje majhne količine butilhidroksitoluena (E321) Ta sestavina draži oči, kožo in sluznice.
English: • Eye disorders: severe decrease of vision (loss of 4 lines or more within 7 days of treatment), visual disturbances such as blurred, hazy or fuzzy vision, flashes of light, decreased vision, and a change in the field of vision in the treated eye such as grey or dark shadows, blind spots or black spots.
Slovenian: • Težave z očmi: zelo zmanjšana ostrina vida (za 4 vrste ali več v enem tednu po zdravljenju), motnje vida, kot so zamegljen, nejasen ali nerazločen vid, bliskanje, zmanjšana ostrina vida in spremembe v vidnem polju zdravljenega očesa, kot so sive ali temne sence, slepe pege ali temne pike.
English: Severely reduced visual acuity, equivalent to 4 lines or more, within seven days after treatment was reported in 2.1 % of the verteporfin-treated patients in the placebo-controlled ocular Phase III clinical studies and in less than 1 % of patients in uncontrolled clinical studies.
Slovenian: V oftalmoloških s placebom kontroliranih kliničnih študijah faze III so poročali o močnem poslabšanju vida, ki ustreza 4 vrstam ali več in do katerega pride v 7 dneh po zdravljenju, in sicer pri 2,1 % bolnikov, zdravljenih z verteporfinom, in pri manj kot 1 % bolnikov v nekontroliranih kliničnih študijah.
English: - If, during the infusion, Visudyne goes outside the vein, and especially if the affected area is exposed to light, this can cause pain, swelling, blistering and a change in skin colour in the area of the leakage.
Slovenian: - Če zdravilo Visudyne med infundiranjem teče mimo vene v okolno tkivo, posebno še, če je prizadeti predel izpostavljen svetlobi, lahko to povzroči bolečino, edem, nastajanje mehurjev in spremembo barve kože v predelu, kjer je zdravilo steklo mimo vene.
English: At month 12, there was a benefit of Visudyne for the primary efficacy endpoint (percentage of patients who lost less than 3 lines of visual acuity) - 86% for Visudyne versus 67% for placebo, p=0.011.
Slovenian: Po 12 mesecih je imelo zdravilo Visudyne prednost glede primarnega cilja opazovanja glede učinkovitosti (odstotek bolnikov, ki so izgubili za manj kot 3 vrste ostrine vida) - 86 % za zdravilo Visudyne proti 67 % za placebo, p=0,011.
English: One multicentre, double-masked, placebo-controlled, randomised study (BPD OCR 003 PM [VIPPM]) was conducted in patients with subfoveal choroidal neovascularisation caused by pathological myopia.
Slovenian: Ena multicentrična dvojno maskirana s placebom kontrolirana randomizirana študija (BPD OCR 003 PM [VIP-PM]) je bila opravljena pri bolnikih s subfovealno horioidalno neovaskularizacijo, ki jo je povzročila bolezenska kratkovidnost.
English: Other medicines and Visudyne
Slovenian: Druga zdravila in zdravilo Visudyne
English: A group of patients who had occult with no classic lesions (n=258) showed a statistically significant difference of 13.7% in favour of Visudyne compared to placebo (45.2% versus 31.5%, p=0.032).
Slovenian: V podskupini bolnikov z okultnimi, a brez klasičnih lezij (n=258) se je pokazala statistično značilna razlika 13,7 % v korist zdravila Visudyne v primerjavi s placebom (45,2 % proti 31,5 %, p=0,032).
English: Visudyne therapy should be considered carefully in patients with moderate hepatic impairment or biliary obstruction since no experience has been gained in these patients.
Slovenian: Odločitev glede zdravljenja z zdravilom Visudyne je treba skrbno preudariti pri bolnikih z zmerno okvaro jeter ali obstrukcijo žolčnih izvodil, ker z uporabo zdravila pri teh bolnikih ni nikakršnih izkušenj.
English: If material is spilled, it should be contained and wiped up with a damp cloth.
Slovenian: Če se raztopina polije, jo obrišite z vlažno krpo.
English: General symptoms can include headache, malaise, syncope, hyperhydrosis, dizziness, rash, urticaria, pruritus, dyspnoea, flushing, and changes in blood pressure and heart rate.
Slovenian: Splošni simptomi lahko vključujejo glavobol, slabo počutje, sinkopo, znojenje, omotičnost, izpuščaj, urtikarijo, srbenje, dispnejo, vročinske oblive in spremembe krvnega tlaka ter srčne frekvence.
English: The VIP-AMD included patients with occult with no classic subfoveal CNV with a visual acuity score of >50 letters (20/100).
Slovenian: V študijo VIP-AMD so bili vključeni bolniki z okultno, a brez klasične subfovealne CNV z oceno vidne ostrine >50 črk (20/100).
English: The selectivity of PDT using verteporfin is based, in addition to the localised light exposure, on selective and rapid uptake and retention of verteporfin by rapidly proliferating cells including the endothelium of choroidal neovasculature.
Slovenian: Osnova selektivnosti fotodinamične terapije (PDT) z verteporfinom je poleg lokalizirane izpostavljenosti svetlobi tudi dejstvo, da celice, ki se hitro razraščajo, vključno z endotelijem horioidalne neovaskularne lezije, selektivno in hitro privzemajo in zadržujejo verteporfin.
English: Visudyne is used for the treatment of predominantly classic choroidal neovascularisation in adults with age-related macular degeneration, and also for the treatment of all types of choroidal neovascularisation in adults with pathological myopia.
Slovenian: Zdravilo Visudyne se uporablja za zdravljenje pretežno klasične horioidalne neovaskularizacije pri odraslih s starostno degeneracijo makule, pa tudi za zdravljenje vseh vrst horioidalne neovaskularizacije pri odraslih z bolezensko kratkovidnostjo.
English: Visudyne is indicated for the treatment of - adults with exudative (wet) age-related macular degeneration (AMD) with predominantly classic subfoveal choroidal neovascularisation (CNV) or - adults with subfoveal choroidal neovascularisation secondary to pathological myopia.
Slovenian: Zdravilo Visudyne je indicirano za zdravljenje - odraslih z eksudativno (vlažno) obliko starostne degeneracije makule (AMD) s prevladujočo klasično subfovealno horioidalno neovaskularizacijo (CNV) ali - odraslih s subfovealno horioidalno neovaskularizacijo zaradi bolezenske kratkovidnosti.
English: At month 24, 79% Visudyne patients versus 72% placebo patients had lost less than 3 lines of visual acuity (p=0.38).
Slovenian: Po 24 mesecih je 79 % bolnikov z zdravilom Visudyne in 72 % bolnikov s placebom izgubilo manj kot 3 vrste ostrine vida (p=0,38).
English: The higher incidence of back pain during infusion in the Visudyne group was not associated with any evidence of haemolysis or allergic reaction and usually resolved by the end of the infusion.
Slovenian: Visudyne, ni bila povezana z znaki hemolize ali alergijske reakcije in je navadno do konca infundiranja izginila.
English: In the VIP-PM study in pathological myopia, the average number of treatments per year were 3.5 in the first year after diagnosis and 1.8 in the second for the randomised placebo-controlled phase and 0.4 in the third year, 0.2 in the fourth and 0.1 in the fifth year for the open-label extension phase.
Slovenian: V študiji VIP-PM, opravljeni pri bolnikih z bolezensko kratkovidnostjo, je bilo povprečno število ciklusov zdravljenja na leto v randomizirani, s placebom kontrolirani fazi 3,5 v prvem letu po diagnozi in 1,8 v drugem letu, v odprti podaljšani fazi pa 0,4 v tretjem letu, 0,2 v četrtem in 0,1 v petem letu.
English: It takes 83 seconds to deliver the laser dose required to activate Visudyne.
Slovenian: Za odmerek laserske svetlobe, potreben za aktivacijo zdravila Visudyne, je potrebnih 83 sekund.
English: Both vasovagal and hypersensitivity reactions are associated with general symptoms such as syncope, sweating, dizziness, rash, dyspnoea, flushing, and changes in blood pressure and heart rate.
Slovenian: Tako vazovagalne kot preobčutljivostne reakcije so povezane s splošnimi simptomi, kot so sinkopa, znojenje, omotičnost, izpuščaj, dispneja, vročinski oblivi in spremembe krvnega tlaka ter srčne frekvence.
English: 364 patients (244 verteporfin, 120 placebo) were enrolled in this study.
Slovenian: V to študijo je bilo vključenih 364 bolnikov (244 verteporfin, 120 placebo).
English: A total of 120 patients (81 Visudyne, 39 placebo) were enrolled in the study.
Slovenian: V študijo je bilo vključenih skupaj 120 bolnikov (81 zdravilo Visudyne, 39 placebo).
English: A higher percentage of patients who received Visudyne, compared with those who received placebo, experienced adverse events (88.1% versus 81.7%), associated adverse events (23.0% versus 7.5%), events leading to discontinuation (11.9% versus 3.3%) and events leading to death (n=10 [4.1%] versus n=1 [0.8%]).
Slovenian: Med bolniki, ki so prejemali zdravilo Visudyne, je v primerjavi s tistimi, ki so prejemali placebo, pri večjem deležu prišlo do neželenih dogodkov (88,1 % proti 81,7 %), do povezanih neželenih dogodkov (23,0 % proti 7,5 %), do dogodkov, zaradi katerih so prenehali sodelovati v študiji, (11,9 % proti 3,3 %) in do dogodkov, ki so se končali s smrtjo (n=10 [4,1 %] proti n=1 [0,8 %]).
English: The VIO study included patients with occult with no classic subfoveal CNV with a visual acuity score of 73-34 letters (20/40-20/200), and patients with lesions >4 MPS disc areas were to have baseline visual acuity <65 letters (<20/50).
Slovenian: V študijo VIO so bili vključeni bolniki z okultno, a brez klasične subfovealne CNV z oceno vidne ostrine 73-34 črk (20/40-20/200) in bolniki z lezijami, ki so bile večje od 4 MPS površin papile, in izhodiščno vidno ostrino <65 črk (<20/50).
English: • General disorders: feeling sick (nausea), sunburn-like reactions, tiredness, infusion-related reaction, primarily presented as chest pain or back pain, and increased cholesterol levels.
Slovenian: • Splošne težave: občutek slabosti (navzea), sončnim opeklinam podobne reakcije, utrujenost, z infuzijo povezana reakcija, ki se kaže zlasti kot bolečina v prsnem košu ali bolečine v hrbtu, in zvišana raven holesterola.
English: After Visudyne treatment you may have some vision problems, such as abnormal or decreased vision, which may be temporary.
Slovenian: Po zdravljenju z zdravilom Visudyne lahko nastopijo težave z vidom, na primer motnje ali poslabšanje vida, kar je lahko prehodno.
English: The vial and any unused portion of reconstituted solution should be discarded after single use.
Slovenian: Vialo in morebiti neporabljeni del rekonstituirane raztopine po enkratni uporabi zavrzite.
English: A maximum 2-fold inter-individual variation in plasma concentrations at Cmax (immediately after end of the infusion) and at the time of light administration was found for each Visudyne dose administered.
Slovenian: Pri vseh uporabljenih odmerkih zdravila Visudyne je bila ugotovljena največ dvakratna variabilnost plazemskih koncentracij med posamezniki pri Cmax (takoj po koncu infundiranja) in v času osvetlitve.
English: This study also included patients with classic containing CNV with a visual acuity score >70 letters (20/40).
Slovenian: V to študijo so bili vključeni tudi bolniki s CNV, ki je bila deloma klasična, in z oceno vidne ostrine >70 črk (20/40).
English: Since verteporfin is excreted primarily via the biliary (hepatic) route, increased verteporfin exposure is possible.
Slovenian: Verteporfin se izloča predvsem z žolčem (preko jeter), zato bi lahko prišlo do povečane izpostavljenosti verteporfinu.
English: Treatment of the second eye with Visudyne
Slovenian: Zdravljenje drugega očesa z zdravilom Visudyne
English: Reconstitute Visudyne in 7.0 ml water for injections to produce 7.5 ml of a 2.0 mg/ml solution.
Slovenian: Rekonstituirajte zdravilo Visudyne v 7,0 ml vode za injekcije, tako da nastane 7,5 ml raztopine s koncentracijo 2,0 mg/ml.
English: The percentage of patients who lost less than 1.5 lines was 72% for Visudyne and 44% for placebo (p=0.003).
Slovenian: Odstotek bolnikov, ki so izgubili manj kot 1,5 vrste, je bil 72 % (zdravilo Visudyne) proti 44 % (placebo), (p=0,003).
English: Extravasation of the solution for infusion
Slovenian: Ekstravazacija raztopine za infundiranje
English: Visudyne contains the active substance verteporfin, which is activated by light from a laser in a treatment called photodynamic therapy.
Slovenian: Zdravilo Visudyne vsebuje zdravilno učinkovino verteporfin, ki jo pri zdravljenju, imenovanem fotodinamično zdravljenje, aktiviramo z lasersko svetlobo.
English: This effect was not observed in conscious non-sedated pigs, or in any other species, including man. Verteporfin at more than 5 times the expected maximum plasma concentration in treated patients, caused a low level of complement activation in human blood in vitro.
Slovenian: Verteporfin je v plazemski koncentraciji, več kot petkrat višji od pričakovane najvišje plazemske koncentracije pri zdravljenih bolnikih, povzročil nizko raven aktivacije komplementa v človeški krvi in vitro.
English: It is important to follow the above recommendations to achieve the optimal treatment effect.
Slovenian: Da bi zdravnik lahko dosegel najboljši učinek zdravljenja, je pomembno, da se ravna po zgornjih priporočilih.
English: Lactose monohydrate, dimyristoyl phosphatidylcholine, egg phosphatidylglycerol, ascorbyl palmitate, butylated hydroxytoluene (E321).
Slovenian: Laktoza monohidrat, dimiristoilfosfatidilholin, jajčni fosfatidilglicerol, askorbilpalmitat, butilhidroksitoluen (E321).
English: Most adverse reactions were mild to moderate and transient in nature.
Slovenian: Neželeni učinki so bili večinoma prehodni in blago do zmerno izraženi.
English: What Visudyne is and what it is used for What you need to know before you are given Visudyne How Visudyne is used
Slovenian: Kaj je zdravilo Visudyne in za kaj ga uporabljamo Kaj morate vedeti, preden boste dobili zdravilo Visudyne Kako uporabljati zdravilo Visudyne Možni neželeni učinki
English: Shelf-life after reconstitution and dilution
Slovenian: Rok uporabnosti po raztopitvi (rekonstituciji) in razredčenju
English: • General disorders: vasovagal reactions (fainting), sweating, flushing, or changes in blood pressure.
Slovenian: • Splošne težave: vazovagalne reakcije (izguba zavesti), znojenje, vročinski oblivi in spremembe krvnega tlaka.
English: A higher percentage of patients who received Visudyne, compared with those who received placebo, experienced adverse events (89.3% versus 82.5 %), associated adverse events (42.7% versus 18.4%) and events leading to discontinuation (6.2% versus 0.9%).
Slovenian: Med bolniki, ki so prejemali zdravilo Visudyne, je v primerjavi s tistimi, ki so prejemali placebo, pri večjem deležu prišlo do neželenih dogodkov (89,3 % proti 82,5 %), do povezanih neželenih dogodkov (42,7 % proti 18,4 %) in do dogodkov, zaradi katerih so prenehali sodelovati v študiji (6,2 % proti 0,9 %).
English: Lactose monohydrate Egg phosphatidylglycerol Dimyristoyl phosphatidylcholine Ascorbyl palmitate Butylated hydroxytoluene (E321)
Slovenian: 6.1 Seznam pomožnih snovi laktoza monohidrat jajčni fosfatidilglicerol dimiristoilfosfatidilholin askorbilpalmitat butilhidroksitoluen (E321)
English: Visudyne precipitates in sodium chloride solution.
Slovenian: Zdravilo Visudyne se v raztopini natrijevega klorida obarja.
English: There are no human fertility data for verteporfin.
Slovenian: O vplivu verteporfina na plodnost pri ljudeh ni nobenih podatkov.
English: Visudyne should be administered only by ophthalmologists experienced in the management of patients with age-related macular degeneration or with pathological myopia.
Slovenian: Zdravilo Visudyne naj aplicirajo samo oftalmologi, ki imajo izkušnje z zdravljenjem bolnikov s starostno degeneracijo makule ali z bolezensko kratkovidnostjo.
English: • Eye disorders: tear in the coloured layer of the retina, swelling or fluid retention in the macula.
Slovenian: • Težave z očmi: raztrganje pigmentnega dela mrežnice, otekanje ali zadrževanje tekočine v makuli.
English: • Infusion site side effects: as with other types of injections, some patients experienced blistering.
Slovenian: • Neželeni učinki na mestu infundiranja: kot pri drugih vrstah injiciranja je pri nekaterih bolnikih prišlo do nastajanja mehurjev.
English: Dark green to black powder.
Slovenian: prašek za raztopino za infundiranje Temnozelen do črn prašek.
English: Visudyne is not indicated in this population.
Slovenian: Zdravilo Visudyne pri tej populaciji ni indicirano.
English: Other photosensitising agents
Slovenian: Druga zdravila, ki fotosenzitizirajo
English: However the pharmacological characteristics do not indicate any need to adjust the dose (see “Biotransformation” and “Elimination” under section 5.2).
Slovenian: Uporabe zdravila Visudyne pri bolnikih z okvaro ledvic niso proučevali, vendar farmakološke lastnosti učinkovine ne kažejo na potrebo po prilagajanju odmerkov (glejte podpoglavji “Biotransformacija” in “Izločanje” v poglavju 5.2).
English: The following adverse reactions were considered potentially related to Visudyne therapy.
Slovenian: Za naslednje neželene učinke velja, da bi bili lahko povezani z zdravljenjem z zdravilom Visudyne.
English: Mutagenicity
Slovenian: Mutageno delovanje
English: The volume of distribution of around 0.60 l/kg at steady state and clearance of around 101 ml/h/kg has been reported following a 10-minute infusion in dose range of 3-14 mg/m2.
Slovenian: Po 10-minutni infuziji odmerka 3-14 mg/m so v stanju dinamičnega ravnovesja zabeležili volumen porazdelitve približno 0,60 l/kg in očistek približno 101 ml/h/kg.
English: For a dose of 6 mg/m body surface (the dose recommended for the treatment) dilute the required amount of Visudyne solution in dextrose 50 mg/ml (5 %) solution for infusion to a final volume of 30 ml.
Slovenian: Za odmerek 6 mg/m telesne površine (za zdravljenje priporočeni odmerek) razredčite potrebno količino raztopine zdravila Visudyne v 50 mg/ml (5 %) raztopini dekstroze za infundiranje do končnega volumna 30 ml. Ne uporabljajte raztopine natrijevega klorida.
English: The pharmacokinetics of verteporfin have been reported to be similar in healthy Caucasian and Japanese men after a dose of 6 mg/m2 by a 10-minute infusion.
Slovenian: Poročali so, da je farmakokinetika verteporfina po odmerku 6 mg/m2 z 10-minutno infuzijo približno enaka pri zdravih belcih in Japoncih moškega spola.
English: To avoid extravasation, a free-flowing intravenous line should be established before starting Visudyne infusion and the line should be monitored.
Slovenian: Za preprečitev ekstravazacije je treba pred začetkom infundiranja zdravila Visudyne nastaviti stalen intravenski kanal in ga kontrolirati.
English: Each vial contains 15 mg of verteporfin.
Slovenian: Ena viala vsebuje 15 mg verteporfina.
English: Visudyne is contraindicated in patients with severe hepatic impairment (see section 4.3).
Slovenian: Pri bolnikih s hudo okvaro jeter je uporaba zdravila Visudyne kontraindicirana (glejte poglavje 4.3).
English: Prolonged exposure to light from light-emitting medical devices such as pulse oximeters should also be avoided for 48 hours following Visudyne administration.
Slovenian: V času do oseminštirideset ur po uporabi zdravila Visudyne se je potrebno izogibati dolgotrajnejšemu izpostavljanju svetlobi iz medicinskih naprav, ki oddajajo svetlobo, na primer iz pulznih oksimetrov.
English: Infusion-related back and chest pain, which may radiate to other areas, including, but not limited to, the pelvis, shoulder girdle or rib cage.
Slovenian: Z infundiranjem povezana bolečina v križu in prsih, ki lahko seva v druge predele, med drugim v medenico, ramenski obroč ali prsni koš.
English: Myocardial infarction has been reported, particularly in patients with previous cardiovascular history, sometimes within 48 hours after the infusion.
Slovenian: Do miokardnega infarkta je včasih prišlo v 48 urah po infuziji.
English: Patients should be under close medical supervision during the Visudyne infusion.
Slovenian: Med infundiranjem zdravila Visudyne morajo biti bolniki pod strogim medicinskim nadzorom.
English: Reconstituted Visudyne is an opaque dark green solution.
Slovenian: Rekonstituirano zdravilo Visudyne je neprozorna temnozelena raztopina.
English: Chest pain, vasovagal reactions and hypersensitivity reactions related to Visudyne infusion have been reported.
Slovenian: Poročali so o bolečini v prsih, vazovagalnih reakcijah in preobčutljivostnih reakcijah na infuzijo zdravila Visudyne.
English: Vasovagal reactions and hypersensitivity reactions related to Visudyne infusion have been reported.
Slovenian: Poročali so o vazovagalnih reakcijah in preobčutljivostnih reakcijah na infuzijo zdravila Visudyne.
English: Visudyne 15 mg powder for solution for infusion
Slovenian: Visudyne 15 mg prašek za raztopino za infundiranje
English: Two randomised, placebo-controlled, double-masked, multicentre, 24-month studies (BPD OCR 003 AMD, or Verteporfin in Photodynamic Therapy-AMD [VIP-AMD], and BPD OCR 013, or Visudyne in Occult Choroidal Neovascularisation [VIO]) were conducted in patients with AMD characterised by occult with no classic subfoveal CNV.
Slovenian: Pri bolnikih z AMD, za katero je bila značilna okultna CNV brez klasične subfovealne CNV, so izvedli dve randomizirani s placebom kontrolirani dvojno maskirani multicentrični 24-mesečni študiji (BPD OCR 003 AMD ali Verteporfin in Photodynamic Therapy-AMD [VIP-AMD] in BPD OCR 013 ali Visudyne in Occult Choroidal Neovascularization [VIO].
English: For a dose of 6 mg/m body surface (see section 4.2) dilute the required amount of Visudyne solution in dextrose 50 mg/ml (5%) solution for infusion to a final volume of 30 ml.
Slovenian: Za odmerek 6 mg/m telesne površine (glejte poglavje 4.2) razredčite potrebno količino raztopine zdravila Visudyne v 50 mg/ml (5 %) raztopini dekstroze za infundiranje do končnega volumna 30 ml. Ne uporabljajte raztopine natrijevega klorida (glejte poglavje 6.2).
English: Retinal pigment epithelial tear, macular oedema.
Slovenian: pogostnost neznana raztrganje pigmentnega epitelija mrežnice, makularni edem
English: Therefore it must be washed off extensively with water in the event of direct contact.
Slovenian: V primeru neposrednega stika z zdravilom Visudyne je potrebno temeljito spiranje z vodo.
English: There are no clinical data on the use of Visudyne in anaesthetised patients.
Slovenian: O uporabi zdravila Visudyne pri anesteziranih bolnikih ni kliničnih podatkov.
English: Visudyne 15 mg powder for solution for infusion verteporfin
Slovenian: Visudyne 15 mg prašek za raztopino za infundiranje verteporfin intravenska uporaba
English: After single use the vial and any unused portion of reconstituted solution should be disposed of after single use in accordance with local requirements.
Slovenian: Vialo in morebiten neporabljen ostanek zdravila po enkratni uporabi zavrzite v skladu z lokalnimi predpisi.
English: What Visudyne is used for Visudyne is used to treat the wet form of age-related macular degeneration and pathological myopia.
Slovenian: Zdravilo Visudyne se uporablja za zdravljenje vlažne oblike starostne degeneracije makule in bolezenske kratkovidnosti.